The Claim
In ZSF1 obese rats with HFpEF, administration of low-dose semaglutide (30 nmol/kg twice weekly for 16 weeks) significantly reduces intramyocardial and hepatic lipid accumulation as quantified by transmission electron microscopy and Oil Red O staining, independent of weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese ZSF1 rats with heart failure with preserved ejection fraction, a specific low dose of semaglutide given twice weekly for 16 weeks reduces fat buildup in the heart and liver, regardless of whether body weight changes.
See the scientific wording
In ZSF1 obese rats with HFpEF, low-dose semaglutide (30 nmol/kg twice weekly for 16 weeks) significantly reduced intramyocardial and hepatic lipid accumulation, as quantified by transmission electron microscopy and Oil Red O staining, independent of weight loss.
Semaglutide activates receptors on heart and liver cells, turning on genes that break down fats for energy and turning off genes that make new fats. This shifts the cells from storing fat to burning it, clearing excess fat from heart and liver tissue without changing body weight.
What the research says
1 studyIn rats with heart and liver problems from too much fat, a small dose of semaglutide cleaned the fat out of their heart and liver cells—even though the rats didn’t lose weight. This means the drug works directly on fat buildup, not just by making you thinner.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.